Opioid-induced immunosuppression and carcinogenesis promotion theories create the newest trend in acute and chronic pain pharmacotherapy

Urszula Kosciuczuk, Pawel Knapp, Anna Maria Lotowska-Cwiklewska, Urszula Kosciuczuk, Pawel Knapp, Anna Maria Lotowska-Cwiklewska

Abstract

Opioids are the main group of pharmacological agents used during the perioperative period and provide a sedative and analgesic component. The observations of opioid consumption in West Europe indicate that this group of drugs is widely used in chronic noncancer pain therapy. Nearly 20 years ago, the first publications indicating that opioids, as an element of perioperative pharmacotherapy in oncologic patients, increase the risk of tumor recurrence and affect further prognosis were presented. The actual publications suggest that there are multifactorial, complex mechanisms underlying the immunological impact and carcinogenesis promotion of opioids and that the intensity varies depending on the type of opioid. There are also questions about the immunosuppressive effects among patients receiving opioids in the treatment of chronic noncancer pain. The aim of the review article is to present information about the action of opioids on the immune system in carcinogenic settings and to define the clinical usefulness of this pharmacological phenomenon.

Conflict of interest statement

No potential conflict of interest was reported.

References

    1. Bennett MI, Eisenberg E, Ahmedzai SH, Bhaskar A, O'Brien T, Mercadante S, et al. Standards for the management of cancer-related pain across Europe-A position paper from the EFIC Task Force on Cancer Pain. Eur J Pain. 2019;23(4):660–8. doi: 10.1002/ejp.1346.
    1. Janah A, Bouhnik AD, Cortaredona S, Mancini J, Bousquet PJ, Peretti-Watel P, et al. Opioid analgesics prescription in people with and without cancer in France. J Opioid Manag. 2018;14(4):245–56.
    1. Al-Hashimi M, Scott SW, Thompson JP, Lambert DG. Opioids and immune modulation: more question than answers. Br J Anaesth. 2013;111(1):80–8. doi: 10.1093/bja/aet153.
    1. Plein LM, Rittner HL. Opioids and the immune system - friend or foe. Br J Pharmacol. 2018;175(14):2717–25. doi: 10.1111/bph.13750.
    1. Ninkovic J, Roy S. Role of the mu-opioid receptor in opioid modulation of immune function. Amino Acids. 2013;45(1):9–24. doi: 10.1007/s00726-011-1163-0.
    1. Stein C. Opioids, sensory systems and chronic pain. Eur J Pharmacol. 2013;716(1-3):179–87. doi: 10.1016/j.ejphar.2013.01.076.
    1. Machelska H, Stein C. Immune mechanisms in pain control. Anesth Analg. 2002;95(4):1002–8. doi: 10.1213/00000539-200210000-00039.
    1. Garcia JB, Cardoso MG, Dos-Santos MC. Opioids and the immune system: clinical relevance. Rev Bras Anestesiol. 2012;62(5):709–18. doi: 10.1016/S0034-7094(12)70169-1.
    1. Filipczak-Bryniarska I, Nowak B, Sikora E, Nazimek K, Woroń J, Wordliczek J, et al. The influence of opioids on the humoral and cell-mediated immune responses in mice. The role of macrophages. Pharmacol Rep. 2012;64(5):1200–15. doi: 10.1016/S1734-1140(12)70916-7.
    1. Kwiatkowska K, Mika J. The importance of chemokines in neuropathic pain development and opioid analgesic potency. Pharmacol Rep. 2018;70(4):821–30. doi: 10.1016/j.pharep.2018.01.006.
    1. Sacerdote P. Opioids and the immune system. Palliat Med. 2006;20(Suppl 1):s9–15. doi: 10.1191/0269216306pm1124oa.
    1. Wei G, Moss J, Yuan Ch. Opioid-induced immunosuppression: is it centrally mediated or peripherally mediated? Biochem Pharmacol. 2003;65(11):1761–6. doi: 10.1016/S0006-2952(03)00085-6.
    1. Tabellini G, Borsani E, Benassi M, Patrizi O, Ricotta D, Caimi L, et al. Effects of opioid therapy on human natural killer cells. Int Immunopharmacol. 2014;18(1):169–74. doi: 10.1016/j.intimp.2013.11.015.
    1. Boland JW, Pockley AG. Influence of opioids on immune function in patients with cancer pain: from bench to bedside. Br J Pharmacol. 2018;175(14):2726–36. doi: 10.1111/bph.13903.
    1. Machelska H. Control of neuropathic pain by immune cells and opioids. CNS Neurol Disord Drug Targets. 2011;10(5):559–70. doi: 10.2174/187152711796234952.
    1. Levins KJ, Prendeville S, Conlon S, Buggy DJ. The effect of anesthetic technique on µ-opioid receptor expression and immune cell infiltration in breast cancer. J Anesth. 2018;32(6):792–6. doi: 10.1007/s00540-018-2554-0.
    1. Filipczak-Bryniarska I, Nazimek K, Nowak B, Kozłowski M, Wasik M, Bryniarski K. In contrast to morphine, buprenorphine enhances macrophage-induced humoral immunity and, as oxycodone, slightly suppresses the effector phase of cell-mediated immune response in mice. Int Immunopharmacol. 2018;54:344–53. doi: 10.1016/j.intimp.2017.11.039.
    1. Lennon FE, Mirzapoiazova T, Mambetsariev B, Poroyko V, Salgia R, Moss J, et al. The u opioid receptor promotes opioid and growth factor-induced proliferation, migration and epithelial mesenchymal transition in human lung cancer. PLoS One. 2014;9(3):e91577. doi: 10.1371/journal.pone.0091577.
    1. Lennon FE, Mirzapoiazova T, Mambetsariev B, Salgia R, Moss J, Singleton PA. Overexpression of the µ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology. 2012;116(4):857–67. doi: 10.1097/ALN.0b013e31824babe2.
    1. Connolly C, Madden SF, Buggy DJ, Gallagher HC. Expression of anaesthestic and analgesic drug target genes in excised breast tumor tissue: Association with clinical disease recurrence or metastasis. PLoS ONE. 2017;12(5):e0177105. doi: 10.1371/journal.pone.0177105.
    1. Zylla D, Gourley BL, Vang D, Jackson S, Boatman S, Lindgren B, et al. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer. 2013;119(23):4103–10. doi: 10.1002/cncr.28345.
    1. Singleton PA, Mirzapoiazova T, Hasina R, Salgia R, Moss J. Increased µ-opioid receptor expression in metastatic lung cancer. Br J Anaesth. 2014;113(Suppl 1):i103–8. doi: 10.1093/bja/aeu165.
    1. Toyama K, Kiyosawa N, Watanabe K, Ishizuka H. Identification of Circulating miRNAs Differentially Regulated by Opioid Treatment. Int J Mol Sci. 2017;18(9):pii E1991. doi: 10.3390/ijms18091991.
    1. Mahdian-Shakib A, Dorostkar R, Tat M, Hashemzadeh MS, Saidi N. Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer. Biomed Pharmacother. 2016;84:592–600. doi: 10.1016/j.biopha.2016.09.087.
    1. Cho JS, Lee MH, Kim SI, Park S, Park HS, Oh E, et al. The Effects of Perioperative Anesthesia and Analgesia on Immune Function in Patients Undergoing Breast Cancer Resection: A Prospective Randomized Study. Int J Med Sci. 2017;14(10):970–6. doi: 10.7150/ijms.20064.
    1. Cui JH, Jiang WW, Liao YJ, Wang QH, Xu M, Li Y. Effects of oxycodone on immune function in patients undergoing radical resection of rectal cancer under general anesthesia. Medicine. 2017;96(31):e7519. doi: 10.1097/MD.0000000000007519.
    1. Shao YJ, Liu WS, Guan BQ, Hao JL, Ji K, Cheng XJ, et al. Contribution of Opiate Analgesics to the Development of Infections in Advanced Cancer Patients. Clin J Pain. 2017;33(4):295–9. doi: 10.1097/AJP.0000000000000405.
    1. Naghibzadeh Tahami A, Khanjani N, Yazdi Feyzabadi V, Varzandeh M, Haghdoost AA. Opium as a risk factor for upper gastrointestinal cancers: a population-based case-control study in Iran. Arch Iran Med. 2014;17(1):2–6. .
    1. Akbari M, Naghibzadeh-Tahami A, Khanjani N, Baneshi MR, Kamali E, Hesampour M, et al. Opium as a Risk Factor for Bladder Cancer: A Population-based Case-control Study in Iran. Arch Iran Med. 2015;18(9):567–71. .
    1. Naghibzadeh-Tahami A, Yazdi Feyzabadi V, Khanjani N, Ashrafi-Asgarabad A, Alizaeh H, Borhaninejad VR, et al. Can Opium Use Contribute to a Higher Risk of Colorectal Cancers? A Matched Case-control Study in Iran. Iran J Public Health. 2016;45(10):1322–31.
    1. Shakeri R, Kamangar F, Mohamadnejad M, Tabrizi R, Zamani F, Mohamadkhani A, et al. Opium use, cigarette smoking, and alcohol consumption in relation to pancreatic cancer. Medicine. 2016;95(28):e3922. doi: 10.1097/MD.0000000000003922.
    1. Moossavi S, Mohamadnejad M, Pourshams A, Poustchi H, Islami F, Sharafkhah M, et al. Opium Use and Risk of Pancreatic Cancer: A Prospective Cohort Study. Cancer Epidemiol Biomarkers Prev. 2018;27(3):268–73. doi: 10.1158/1055-9965.EPI-17-0592.
    1. Rashidian H, Zendehdel K, Kamangar F, Malekzadeh R, Haghdoost AA. An Ecological Study of the Association between Opiate Use and Incidence of Cancers. Addict Health. 2016;8(4):252–60.
    1. Amodeo G, Bugada D, Franchi S, Moschetti G, Grimaldi S, Panerai A, et al. Immune function after major surgical interventions: the effect of postoperative pain treatment. J Pain Res. 2018;11:1297–305. doi: 10.2147/JPR.S158230.
    1. Kavanagh T, Buggy DJ. Can anaesthetic technique effect postoperative outcome? Curr Opin Anesthesiol. 2012;25(2):185–98. doi: 10.1097/ACO.0b013e32834f6c4c.
    1. Kim R. Effects of surgery and anesthetic choice on immunosuppression and cancer recurrence. J Transl Med. 2018;16(1):8. doi: 10.1186/s12967-018-1389-7.
    1. Kim SY, Kim NK, Baik SH, Min BS, Hur H, Lee J, et al. Effects of Postoperative Pain Management on Immune Function After Laparoscopic Resection of Colorectal Cancer: A Randomized Study. Medicine. 2016;95(19):e3602. doi: 10.1097/MD.0000000000003602.
    1. Varrassi G, Fusco M, Skaper SD, Battelli D, Zis P, Coaccioli S, et al. A Pharmacological Rationale to Reduce the Incidence of Opioid Induced Tolerance and Hyperalgesia: A Review. Pain Ther. 2018;7(1):59–75. doi: 10.1007/s40122-018-0094-9.
    1. Eidson LN, Murphy AZ. Inflammatory mediators of opioid tolerance: Implications for dependency and addiction. Peptides. 2019;115:51–8. doi: 10.1016/j.peptides.2019.01.003.
    1. Sacerdote P, Manfredi B, Mantegazza P, Panerai AE. Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Br J Pharmacol. 1997;121(4):834–40. doi: 10.1038/sj.bjp.0701138.
    1. Zajączkowska R, Leppert W, Mika J, Kocot-Kępska M, Woroń J, Wrzosek A, et al. Perioperative Immunosuppression and Risk of Cancer Progression: The Impact of Opioids on Pain Management. Pain Res Manag. 2018;2018:9293704. doi: 10.1155/2018/9293704.
    1. Haroutounian S. Postoperative opioids, endocrine changes, and immunosuppression. Pain Rep. 2018;3(2):e640. doi: 10.1097/PR9.0000000000000640.
    1. Tuerxun H, Cui J. The dual effect of morphine on tumor development. Clin Transl Oncol. 2019;21(6):695–701. doi: 10.1007/s12094-018-1974-5.
    1. Wodehouse T, Demopoulos M, Petty R, Miraki-Moud F, Belhaj A, Husband M, et al. A randomized pilot study to investigate the effect of opioids on immonomarkers using gene expression profiling during surgery. Pain. 2019;160(12):2691–8. doi: 10.1097/j.pain.0000000000001677.
    1. Inagi T, Hoshina H, Suzuki M, Wada M, Bito H, Sakamato A. Remifentanil-induced alterations in neutrophil numbers after surgery. JA Clin Rep. 2016;2(1):5. doi: 10.1186/s40981-016-0031-z.
    1. Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol. 2012;10(6):209–19. doi: 10.1016/j.suponc.2012.05.002.
    1. Ghelardini C, Di Cesare Mannelli L, Bianchi E. The pharmacological basis of opioids. Clin Cases Miner Bone Metab. 2015;12(3):219–21. doi: 10.11138/ccmbm/2015.12.3.219.
    1. Di Cesare Mannelli L, Micheli L, Lucarini E, Ghelardini C. Ultramicronized N-Palmitoylethanolamine Supplementation for Long-Lasting, Low-Dosed Morphine Antinociception. Front Pharmacol. 2018;9:473. doi: 10.3389/fphar.2018.00473.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever